Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on May 17, 2022. The company is listed on The Nasdaq Capital Market. The filing addresses a specific regulatory event regarding the continued listing of its common stock.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance matter.
Material Changes
The material change reported is the Company's receipt of a notice from Nasdaq granting a second 180-calendar-day grace period to regain compliance with Listing Rule 5550(a)(2). The Company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The new compliance deadline is November 14, 2022.
Outlook, Management Commentary, and Risks
- Management Action: The Company expects to effect a reverse stock split if necessary to regain compliance before the expiration of the Second Grace Period.
- Current Status: The notice has no immediate impact on the listing; the stock will continue to trade on The Nasdaq Capital Market subject to other requirements.
- Risks: Failure to regain compliance by November 14, 2022, could result in delisting.
Investor Verification Checklist
- Verify the current trading price of COCP to assess the likelihood of a reverse stock split.
- Monitor future filings for the formal announcement of a reverse stock split ratio and implementation date.
- Confirm the Company's cash position in other filings (e.g., 10-Q or 10-K) to evaluate its ability to fund operations while addressing the listing issue.
- Check for any additional Nasdaq correspondence regarding the grace period status.